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In the manuscript authors describe the application of rasburicase in the treatment of acute
kidney injury in a child with non-malignancy associated hyperuricemia and combined
congenital abnormalities. Rasburicase application was safe, well tolerated and rapidly
effective. The significant fall in serum uric acid levels was accompanied by rising diuresis.
The improvement of renal function prevented the need for dialysis, whichwas favorable for
the patient and markedly reduced the costs of treatment. Rasburicase could be an option in
the treatment of acute kidney injury also in children with marked hyperuricemia of non-
malignancy origin.
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Hyperuricemia plays an important role in the pathogenesis of
acute and chronic diseases including gout, tumor lysis
syndrome (TLS), arterial hypertension, renal failure, coronary
heart disease, left ventricular hypertrophy and metabolic
syndrome [1]. In acute kidney injury (AKI), when the urine flow
is low and pH is acidic, uric acid as the substance poorly
soluble inwater precipitates into crystals in renal tubules. This
results in increased risk of tubular obstruction. Additionally
hyperuricemia is the cause of enhanced synthesis of reactive
oxygen species, renin–angiotensin–aldosterone system acti-
vation, increased endothelin-1 production and nitric oxide
system inhibition, which contributes to the pathogenesis
of AKI [2]. Rasburicase (recombinant urate oxidase) is an
efficient protease in urate depletion, which plays a valuable
role in the treatment of malignancy – associated TLS [3]. Its
action includes uric acid (UA) conversion to more soluble
allantoine. This drug does not cause the accumulation of
intermediate products of purine metabolism pathway such as
xanthine. Intraluminal obstruction of renal tubules by
precipitating uric acid has been avoided [4].
Urate oxidase was produced from cultures of Aspergillus
flavus. It was introduced to the treatment of TLS in Europe in
1974. Now it is used as the recombinant form – rasburicase –
Fasturtec (Sanofi-Aventis, Paris, France). The usage of rasbu-
ricase has eliminated serious immunological complications
caused by non-recombinant compound [5].
There is notmuch data in literature on rasburicase usage in
AKI in children [4]. In this manuscript authors describe the
application of rasburicase in the treatment of AKI in a child
with acute non-malignancy associated hyperuricemia and
combined congenital abnormalities.
Case report
A 5-year-old boy was admitted to pediatric department with
a 4-day history of vomiting, dehydratation and oliguria in the
course of gastro-intestinal infection. Past history was remar-
kable. He had multiply congenital malformations [face
dysmorphy and limb deformation with muscular contractu-
res, hypostature, organic heart disease – significant mitral
insufficiency (+ + +) with ventricular septal defect, corneal and
scleral staphylomas, amaurotic right bulb, congenital cataract
of left eye].
He suffered from AKI 10 months prior to current hospita-
lization. He developed multiorgan dysfunction syndrome after
the reimplantationof artificialmitral valve.He requireddialysis
for 11 days (2 days on peritoneal dialysis, 9 days on continuous
hemodiafiltration). At the age of 3 he had cerebral stroke due to
thrombosis of rightmiddle cerebral artery. From the age of 4 he
had tracheostomy. Additionally boy received antihypertensive
medication, anticoagulant (acenocumarol) for cardiological
purposes, he also continued antiepileptic treatment.
On admission he was pale, fatigued with marked dyspnoe.
On examination artificial right eye bulb (after the rupture of
congenitally deformed bulb), dry oral cavity mucosa, dry skin,
red throat, postoperative scar in sternal area, additionallywere found. No signs of cardiovascular insufficiency were
noted. He remained in sitting position on a wheel chair. His
intellectual development was slightly delayed.
Laboratory test values showed anemia (Hb: 9.6 g/dl), high
platelet count (595 G/L), high leukocyte count (15.2 G/L), meta-
bolic acidosis (HCO3 6.3 mmol/L), hyperuricemia (675 mmol/L),
hyponatremia (130 mmol/L), hypoproteinemia (50.2 g/L),
hypoalbuminemia (21.2 g/L), higher creatinine (84 mmol/L)
and urea values (11.7 mmol/L), high CRP concentration
(79.3 mg/L), high grade proteinuria (3.6–14.0–27.0 g/L) without
the features of nephrotic syndrome. Protrombin time (28.3 s),
INR: 2.6 and APTT (46.2 s) were prolonged. The chest X-ray
revealed bilateral pneumonia. Echocardiographic examination
confirmed artificial mitral valve with maximum gradient
20 mmHg and tricuspid valve insufficiency with pulmonary
hypertension (maximum gradient 60–70 mmHg). Extrarenal
cause of AKI was excluded. On ultrasound typically localized
kidneys with mean length of 10 cm, blurred image and
increased cortex echogenicity were shown.
Conservative treatment of AKI was administered with no
significant improvement. General edema persisted and hype-
ruricemiaworsened.Onday 4th rasburicasewas applied at the
dose 0.1 mg/kg body weight. Daily urine output and values of
selected laboratory parameters on consecutive days are
shown in Fig. 1.
UA concentration significantly dropped during first 24 h
after rasburicase administration and reached normal values.
On day 12 furosemide and dopamine were withdrawn. Renal
replacement therapy was not implemented. Creatinine and
urea values normalized at day 14. Alkalosis persisted from day
5 without supplementation. The increase of serum potassium
concentration and the decrease of calcium were noted as
shown on Fig. 1e and f.
The treatment of pneumoniawas finished at day 20 and the
boy has been discharged. He remained under the strict
nephrological control in out-patient clinic. Mild hyperurice-
mia was present during the time of further observation and
was rather caused by chronic kidney disease than inherited
defect of purine metabolism. Kidney function gradually
deteriorated to reach the stadium 5 of chronic kidney disease
after the 2.5 years from the episode of acute kidney injury.
Discussion
The conservative management of hyperuricaemia involves
the use of allopurinol, high-volume hydration, diuretic
therapy and urine alkalinization. In patients with anuria or
oliguria this method is not effective [6].
Studies mostly in TLS patients confirmed that rasburicase
application is safe,well tolerated and rapidly effective (onset is
present already after 4 h) [3]. The dramatic fall in serum UA
levels is accompanied by rising diuresis. This prevents the
need for dialysis among TLS patients, which is favorable and
markedly reduces the costs of treatment. Hummel et al. [7]
gave low rasburicase doses in oncological patients, starting
from 0.049 mg/kg/24 h and after that adjusting the dose to UA
level with excellent effect. Rasburicase has been proven to
dissolve tubular uric acid crystals. Segura et al. [8] postulated
that rasburicase can also act in urinary tract, fragmentizing
[(Fig._1)TD$FIG]
Fig. 1 – Daily urine output and values of selected laboratory parameters on consecutive days; a – daily urine output, b – uric
acid concentration, c – renal function indices, d – bicarbonate concentration, e – potassium concentration, f – ionized
calcium concentration; red arrow – rasburicase bolus
Ryc. 1 – Dobowa diureza i wartos´ci wybranych parametro´w laboratoryjnych w czasie hospitalizacji; a – dobowe wydalanie moczu,
b – ste˛z˙enie kwasu moczowego, c –wskaz´niki funkcji nerek, d – ste˛z˙enie wodorowe˛glanu, e – ste˛z˙enie potasu, F – ste˛z˙enie wapnia
zjonizowanego; czerwona strzałka – bolus rasburikazy
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applied successfully rasburicase in 2 adults with acute
obstructive nephropathy from renal calculi. De Angelis et al.
[1] showed that after 7 days of the rasburicase more
pronounced antihyperuricemic effect was obtained in men
than in women with renal failure.
In our boy with AKI we considered the use of rasburicase
because of excessively elevated UA serum levels not resolving
after conservative management and to control volume of
infused fluids and manage effective diuresis (Fig. 1c). Boy had
cardiological complications – organic heart abnormality with
pulmonary hypertension – and in his past history suffered
cerebral stroke and artificial mitral valve thrombosis.
The instillation of hemodialysis carried higher risk, and as
he had peritoneal dialysis and peritoneal drainage after
cardiac surgery before, so we could expect the possibility ofperitoneal adhesions. The treatment with one low-dose
rasburicase (0.1 mg/kg body weight) was very efficient and
prevented dialysis. Significant decline of UA serum levels
(Fig. 1a) and normalization of renal indices (Fig. 1b) have been
observed accompanied by metabolic alkalosis (Fig. 1d), hypo-
kalemia (Fig. 1e), and hypocalcemia (Fig. 1f). Metabolic
alterations after the use of rasburicase required potassium
and calcium supplementation (risk of epileptic event).
In line with our observations other authors shown that
alkalinization could be withheld using rasburicase [6]. Other
effects of rasburicase include calcium phosphate tissue
deposition caused by excessive phosphate reabsorption. Go´th
[9] described increased production and high concentration of
hydrogen peroxide during rasburicase treatment. This could
cause hemolysis and methemoglobin formation, in case of
glucose-6-phosphate-dehydrogenaseandcatalasedeficiencies.
p e d i a t r i a p o l s k a 8 7 ( 2 0 1 2 ) 5 2 1 – 5 2 4524Roncal et al. [10] described in rats, that treatment with
rasburicase reversed the inflammatory changes and lessened
tubular injury with an improvement in renal function.
During the prolonged treatment antibodies against rasbu-
ricase have been detected in serum of patients. These
antibodies declined the treatment efficiency. It is hypothesi-
zed that UA might be directly involved in the apoptotic
process. Hobbs et al. treated infantswithAKIwith rasburicase.
They report beneficial effect on lowering serum UA concen-
tration. The side effects of such treatment were absent [11].
In conclusion, rasburicase could be an option in the
treatment of AKI with marked hyperuricemia of non-malig-
nancy origin in children.
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